… In this work, we review and comment upon the challenges and the ‘quo vadis’ in Alzheimer's
disease drug discovery at the beginning of the new millennium. We emphasize recent …

Introduction: As the global burden of Alzheimer’s disease (AD) grows, an effective disease-modifying
therapy remains a distant prospect following the repeated failure of multiple …

… At the same time, the discovery of rare forms of early onset Familial Alzheimer’s disease (FAD)
inherited in an autosomal dominant fashion Citation[5] highlighted the relevance of …

… In addition, new mechanistic rationales for drug discovery in AD that include autophagy
and synaptogenesis have been discovered. Herein, we describe the state-of-the-art of the …

Alzheimer's disease is a progressive and irreversible neurodegenerative disease, associated
with a decreased cognitive function and severe behavioral abnormalities. Due to its …

… By analogy, our understanding of drug discovery for Alzheimer’s disease (AD) is at a similar
point, the end of the beginning. The development of therapies for AD represents a major …

… in ongoing or future drug development programs. In the present work, challenges in AD
drug discovery and development will be presented along with potential MID3 solutions. …

… disease management; (v) a reorientation of drug discovery programs based on consensual
drug targets and pharmacogenetic protocols; (vi) the updating of regulatory requirements for …

… Over the past decade, the focus of drug discovery and development efforts has shifted toward
DMTs for AD; that is, treatments whose aim is to affect the underlying disease process by …

Alzheimer’s disease (AD) is a priority health problem in advanced societies and in many
emerging and developing countries, with high cost for public health services, an overload on …